Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-FAP-01 DSP-7888 vaccine in familial adenomatous polyposis
jRCT2051200082Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adegramotide + nelatimotide in Colonic Adenomatous Polyposis and colon adenoma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Percentage of patients with newly detected polyps of ≥5 mm in diameter. Started Dec 2020; status: active, not recruiting.
02
Drugs
adegramotide + nelatimotide
03
Conditions
Colonic Adenomatous Polyposiscolon adenoma
Beyond the preview
Go deeper on jRCT2051200082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200082.